Figure 2.

CII-DC-AdTRAIL+DOX treatment effectively prevents CII arthritis. (a) Diagram of treatment protocol as described in Methods. (b) CIA incidence in mice. Arthritis incidence in the different treatment groups was recorded every week until the mice were sacrificed. Shown are the statistically significant differences of the instances of mice that develop arthritis, comparing the CIA–no treatment group with each of the four treatment groups, as determined by the Mann-Whitney U test. (c) DBA1j mice were challenged with CII and treated with CII-DC-AdTRAIL+DOX, CII-DC-AdTRAIL, CII-DC-AdGFP+DOX, or DC-AdTRAIL+DOX. The mice were sacrificed at 19 weeks of age. Tissue sections were stained with H&E. C, cartilage; BM, bone marrow cavity; SLC, synovial lining cells; SH, synovial hyperplasia. Original magnification, ×20. (d) The joint severity score was quantitated using a double-blinded method. The severity score was divided into four levels using the scoring system described in Methods. Each bar represents the mean severity score from ten mice in each treatment group. The asterisk above the bar indicates treatment groups of mice that were significantly different from the CIA–no treatment group of mice. *P < 0.05; **P < 0.01.